https://dash.harvard.edu/entities/publication/73120378-d79a-6bd4-e053-0100007fdf3b
A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells
Background: Reversing multidrug resistance (MDR) has been an important goal for clinical and investigational oncologists. In the last few decades, significant...
reversespaclitaxeldoxorubicinresistanceosteosarcoma